Verastem (VSTM)
(Delayed Data from NSDQ)
$12.13 USD
-0.99 (-7.55%)
Updated May 16, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VSTM 12.13 -0.99(-7.55%)
Will VSTM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VSTM
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Other News for VSTM
Buy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
Buy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive Outlook
RBC Capital Sticks to Their Buy Rating for Verastem (VSTM)
Verastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory Milestones